Can Fite Biopharma Stock Performance
| CANF Stock | USD 2.10 0.05 2.44% |
The firm shows a Beta (market volatility) of 0.8, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Can Fite's returns are expected to increase less than the market. However, during the bear market, the loss of holding Can Fite is expected to be smaller as well. At this point, Can Fite Biopharma has a negative expected return of -0.008%. Please make sure to confirm Can Fite's maximum drawdown, daily balance of power, relative strength index, as well as the relationship between the skewness and day typical price , to decide if Can Fite Biopharma performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Can Fite Biopharma has generated negative risk-adjusted returns adding no value to investors with long positions. Despite nearly stable basic indicators, Can Fite is not utilizing all of its potentials. The latest stock price disturbance, may contribute to mid-run losses for the stockholders. ...more
Actual Historical Performance (%)
One Day Return 5.8 | Five Day Return 8.5 | Year To Date Return 4.83 | Ten Year Return (99.65) | All Time Return (99.73) |
Last Split Factor 1:10 | Dividend Date 2019-05-10 | Last Split Date 2023-01-09 |
1 | Join Can-Fites Exclusive Live Investor Webinar and QA Session on October 29 - StockTitan | 10/07/2024 |
2 | Significant Positive Results from Osteoarthritis Clinical Study in Dogs Treated with Piclidenoson | 10/18/2024 |
3 | Can-Fites namodenoson maintains stock target, buy rating after trial news | 11/12/2024 |
| Begin Period Cash Flow | 3 M |
Can |
Can Fite Relative Risk vs. Return Landscape
If you would invest 222.00 in Can Fite Biopharma on August 30, 2024 and sell it today you would lose (12.00) from holding Can Fite Biopharma or give up 5.41% of portfolio value over 90 days. Can Fite Biopharma is currently does not generate positive expected returns and assumes 4.0832% risk (volatility on return distribution) over the 90 days horizon. In different words, 36% of stocks are less volatile than Can, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Can Fite Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Can Fite's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Can Fite Biopharma, and traders can use it to determine the average amount a Can Fite's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.002
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | CANF |
Estimated Market Risk
| 4.08 actual daily | 36 64% of assets are more volatile |
Expected Return
| -0.01 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| 0.0 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Can Fite is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Can Fite by adding Can Fite to a well-diversified portfolio.
Can Fite Fundamentals Growth
Can Stock prices reflect investors' perceptions of the future prospects and financial health of Can Fite, and Can Fite fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Can Stock performance.
| Return On Equity | -1.58 | ||||
| Return On Asset | -0.57 | ||||
| Operating Margin | (12.96) % | ||||
| Current Valuation | 8.25 M | ||||
| Shares Outstanding | 6.1 M | ||||
| Price To Earning | (3.41) X | ||||
| Price To Book | 5.19 X | ||||
| Price To Sales | 18.82 X | ||||
| Revenue | 743 K | ||||
| Gross Profit | 810 K | ||||
| EBITDA | (8.18 M) | ||||
| Net Income | (7.63 M) | ||||
| Cash And Equivalents | 12.77 M | ||||
| Cash Per Share | 0.47 X | ||||
| Total Debt | 40 K | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 6.78 X | ||||
| Book Value Per Share | 0 X | ||||
| Cash Flow From Operations | (8.44 M) | ||||
| Earnings Per Share | (2.60) X | ||||
| Market Capitalization | 12.56 M | ||||
| Total Asset | 9.99 M | ||||
| Retained Earnings | (158.48 M) | ||||
| Working Capital | 7.89 M | ||||
| Current Asset | 39.51 M | ||||
| Current Liabilities | 5.77 M | ||||
About Can Fite Performance
By analyzing Can Fite's fundamental ratios, stakeholders can gain valuable insights into Can Fite's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Can Fite has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Can Fite has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.76) | (0.80) | |
| Return On Capital Employed | (1.03) | (1.08) | |
| Return On Assets | (0.76) | (0.80) | |
| Return On Equity | (1.22) | (1.28) |
Things to note about Can Fite Biopharma performance evaluation
Checking the ongoing alerts about Can Fite for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Can Fite Biopharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Can Fite Biopharma generated a negative expected return over the last 90 days | |
| Can Fite Biopharma has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 743 K. Net Loss for the year was (7.63 M) with profit before overhead, payroll, taxes, and interest of 810 K. | |
| Can Fite Biopharma currently holds about 12.77 M in cash with (8.44 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.47. | |
| Can Fite Biopharma has a frail financial position based on the latest SEC disclosures | |
| Latest headline from investing.com: Can-Fites namodenoson maintains stock target, buy rating after trial news |
- Analyzing Can Fite's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Can Fite's stock is overvalued or undervalued compared to its peers.
- Examining Can Fite's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Can Fite's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Can Fite's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Can Fite's stock. These opinions can provide insight into Can Fite's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Can Stock analysis
When running Can Fite's price analysis, check to measure Can Fite's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Can Fite is operating at the current time. Most of Can Fite's value examination focuses on studying past and present price action to predict the probability of Can Fite's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Can Fite's price. Additionally, you may evaluate how the addition of Can Fite to your portfolios can decrease your overall portfolio volatility.
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated |